Silence Therapeutics to Present at SVB Securities Global Biopharma Con...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 26, 2024

BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer&rs • Coastal Carolina, Southwestern Law School, and Other Institutions Streamline Accessibility Workflows With YuJa's PDF Remediation • PPG again earns EcoVadis gold rating for sustainability practices, ranks among top 7% of evaluated companies • Nonprofits from Inception Fertility and Caden Lane Team Up to Expand Financial Accessibility to Fertility Care • Aspen Technology Introduces New Strategic Planning for Sustainability Pathways Solution • Webber Marketing Celebrates the 10th Anniversary of the National Battle of the Bands with Exclusive Film Releases on YouTube • ADS-TEC Energy (ADSE) to Host Business Update Call on April 30th Following the Release of Full-Year 2023 Results • Cosmetic Executive Women (CEW) Hosts Achiever Awards • Dual Enrollment Helps High School Students Launch Rewarding Careers • Cross River, Financially CLEAN and Visa Host Financial Literacy Event for NYC Students at the New York Stock Exchange • Gopuff Invites the World to "Bring The Magic" to Everyday Experiences with the Launch of Its Largest-Ever Brand Campaign • United Imaging Healthcare Releases 2023 ESG Report, Advancing Mission of Equal Healthcare for All™ • FOSUN FOR GOOD, CREATING IMPACT: Fosun International Issued its 2023 ESG Report and the Second Climate Information Disclosures R • McCain Foods Plants 18,000 Trees in Wisconsin, Fulfilling 2022 Promise to Plover Community • Operation HOPE and SBA Forge Strategic Alliance to Empower Small Businesses Across America • Manulife Investment Management Announces Forest Climate Fund's Second Close Bringing Total Commitments Up to $334.5 Million • In Support of PEPSI® x Mary J. Blige Strength of a Woman Partnership, The Brand Launches $100,000 Fund to Support Yonkers Wo • Chase Opens Innovative Branch in Bronx’s Grand Concourse Neighborhood • United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52%

Silence Therapeutics to Present at SVB Securities Global Biopharma Conference

LONDON , February 08 /Businesswire/ - Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15^th at 3:00 p.m. ET.

A live webcast of the presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.